Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain.

about

CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort

P2860

Q58698638-90C099E1-4C07-4879-A39D-7C3C6338BA49

P2860

Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain.

Item

http://www.wikidata.org/entity/Q49384614

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain.

@en

Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain.

@nl

type

Item

label

Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain.

@en

Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain.

@nl

prefLabel

Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain.

@en

Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain.

@nl

P1476

Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain.

@en

P2093

Glenn D Braunstein

http://www.w3.org/2001/XMLSchema#string

Robert Morlock

http://www.w3.org/2001/XMLSchema#string

P2860

Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine

Evidence Brief: The Comparative Effectiveness, Harms, and Cost-effectiveness of Pharmacogenomics-guided Antidepressant Treatment versus Usual Care for Major Depressive Disorder

Codeine intoxication associated with ultrarapid CYP2D6 metabolism

Methadone-associated Q-T interval prolongation and torsades de pointes.

Genetic Testing for Opioid Pain Management: A Primer

Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety

Cytochrome P450 pharmacogenetics and cancer.

Opioid pharmacotherapy for chronic noncancer pain: the american experience

Future Directions for Pain Management: Lessons from the Institute of Medicine Pain Report and the National Pain Strategy

Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment.

P304

e615

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/PR9.0000000000000615

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29392230

http://www.w3.org/2001/XMLSchema#string

P932

5777678

http://www.w3.org/2001/XMLSchema#string

Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain.

about

P2860

P2860

Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932